Alnylam Pharmaceuticals will gain access to Helix’s GenoSphere™ cohorts under a newly announced multi‑year agreement aimed at advancing precision medicine development, according to the companies.
The partnership gives Alnylam access to large, de‑identified genomic and longitudinal clinical data sets provided by Helix’s GenoSphere platform, which includes Exome+® sequencing information paired with detailed medical and pharmacy claims.
The company plans to use the data to support its drug discovery efforts, particularly to identify new targets for RNA interference therapeutics that silence genes implicated in various diseases.
Alnylam’s research strategy places emphasis on leveraging human genetics to guide the development of its RNAi medicines, and the agreement is intended to bolster the firm’s ability to discover novel targets across disease areas represented in Helix’s datasets.
Helix’s genomic cohorts feature comprehensive gene sequencing data and curated clinical histories with an average of 13 years of electronic health record information, designed to fuel life sciences research across the development cycle.
Alnylam Pharmaceuticals is a biopharmaceutical company focused on RNAi therapeutics, using genetic insights to inform its drug discovery and development activities across a range of diseases.
